Inclusion Criteria:

          1. a) Safety cohort (Arms A & B): Patients with advanced NSCLC (metastatic or locally
             advanced), for whom there are no other suitable treatment options.-

               -  Able to and likely to be well enough to receive six vaccinations i.e. judged by
                  the Investigator to not require alternate treatment for the duration of the
                  vaccination schedule and period to off trial visit.

               -  Has had sufficient wash out periods from previous treatments as follows:

                  i) four weeks for chemotherapy ii) six weeks for investigational medicinal
                  products (IMPs) iii) eight weeks for immunotherapy (shorter intervals may be
                  acceptable based on half-life of treatment. Eligibility will be confirmed by the
                  Sponsor and CI).

               -  Measurable disease

               -  Biopsiable disease is preferable however patients without biopsiable disease can
                  still be considered for the study.

                  b) Expansion cohort (Arms C & D): NSCLC patients in the adjuvant setting,
                  currently disease free, who have completed all suitable treatment options
                  (chemotherapy +/- surgery).-

               -  Able to and likely to be well enough to receive six vaccinations i.e. judged by
                  the Investigator to not require alternate treatment for the duration of the
                  vaccination schedule and period to off trial visit.

          2. Written (signed and dated) informed consent and be capable of co-operating with
             treatment and follow-up.

          3. Confirmed HLA A*02:01 positive genotype (Treatment arms A and C only).

          4. Life expectancy of at least 12 weeks.

          5. World Health Organisation (WHO) performance status of 0-2.

          6. Haematological and biochemical indices within the ranges shown below. These
             measurements must be performed prior to the patient receiving the first AST-VAC2
             vaccination.

             Laboratory Test and Value required

             Haemoglobin (Hb) ≥9.0 g/dL Absolute neutrophil count (ANC) ≥1.5 x 10^9 /L Platelet
             count ≥100 x 10 ^9/L Lymphocyte count ≥1.0 x 10^9 /L Bilirubin ≤1.5 x upper limit of
             normal (ULN) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) and
             alkaline phosphatase (ALP) ≤ 3.0 x ULN Calculated creatinine clearance > 30 mL/min

          7. 18 years or over at the time consent is given.

        Exclusion Criteria:

          1. Radiotherapy (except for palliative reasons) during the previous four weeks before
             treatment.

          2. Ongoing toxic manifestations of previous treatments greater than CTCAE Grade 1.
             Exceptions to this are alopecia or certain Grade 2 toxicities, which in the opinion of
             the Investigator and the Sponsor should not exclude the patient.

          3. Systemic steroids or other drugs with a likely effect on immune competence are
             forbidden during the trial. The predictable need of their use will preclude the
             patient from trial entry.

          4. Female patients who are able to become pregnant (or are already pregnant or
             lactating). However, those patients who have a negative serum or urine pregnancy test
             before enrolment and agree to use two forms of contraception (one effective form plus
             a barrier method) [oral, injected or implanted hormonal contraception and condom;
             intra-uterine device and condom; diaphragm with spermicidal gel and condom] or agree
             to sexual abstinence*, effective from the first administration of AST-VAC2 throughout
             the trial and for six months afterwards are considered eligible. (treatment arms only)

          5. Male patients with partners of child-bearing potential (unless they agree to take
             measures not to father children by using a barrier method of contraception [condom
             plus spermicide] or to sexual abstinence* effective from the first administration of
             AST-VAC2, throughout the trial and for six months afterwards. Men with partners of
             child-bearing potential must also be willing to ensure that their partner uses an
             effective method of contraception for the same duration for example, hormonal
             contraception, intrauterine device, diaphragm with spermicidal gel or sexual
             abstinence). Men with pregnant or lactating partners must be advised to use barrier
             method contraception (for example, condom plus spermicidal gel) to prevent exposure of
             the foetus or neonate (treatment arms only)

          6. Major thoracic or abdominal surgery from which the patient has not yet recovered.

          7. At high medical risk because of non-malignant systemic disease including active
             uncontrolled infection.

          8. Known to be serologically positive for Hepatitis B, Hepatitis C or Human
             Immunodeficiency Virus (HIV).

          9. Evidence of any ongoing active autoimmune disease.

         10. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease
             (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior
             history of cardiac arrhythmia.

         11. Is a participant or plans to participate in another interventional clinical trial,
             whilst taking part in this Phase I trial of AST-VAC2. Participation in an
             observational trial or interventional clinical trial which does not involve
             administration of an IMP and which would not place an unacceptable burden on the
             patient in the opinion of the Investigator and Medical Advisor would be acceptable.

             Control arm patients:

             If a patient in either of the control arms consequently wishes to consent to another
             treatment trial/withdraw from the trial for other reasons, prior to the end of their
             follow up period, then their follow up information as per Section 7.4, will be
             recorded in the electronic case report form (eCRF) and the patient will be withdrawn
             from the trial.

         12. Any vaccination given within four weeks before the first AST-VAC2 vaccination.

         13. Any planned prophylactic vaccination from trial entry until completion of the AST-VAC2
             vaccinations.

         14. Any condition which might interfere with the patient's ability to generate an immune
             response.

         15. Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for the clinical trial.

               -  Abstinence is only considered to be an acceptable method of contraception when
                  this is in line with the preferred and usual lifestyle of the subject. Periodic
                  abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and
                  withdrawal are not acceptable methods of contraception.